[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-attack\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-attack":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,82,117,176],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100614924","the-role-of-stress-in-cardiac-arrest-cortizol-cpr-100614924",false,"NCT07285915","The Role of Stress in Cardiac Arrest (Cortizol CPR)","Stress as a Key Factor Influencing the Onset and Course of Cardiac Arrest","Cortizol","Inclusion Criteria:\n\n* Cardiac arrest\n* Heart attack\n* 18 - 100 years\n\nExclusion Criteria:\n\n* Disapproval patient´s relatives with the study\n* Chronical treatment with corticoids and antidepresives","ALL","18 Years","100 Years",{"count":21,"type":22},136,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of this study is to assess long-term stress in patients after an out-of-hospital cardiac arrest. To do this, we will measure levels of the stress hormone cortisol in hair samples. Cortisol is produced in larger amounts during periods of ongoing stress and builds up in the hair as it grows. Because hair grows about 1 cm per month, a 3 cm hair sample can show your average stress level over the past three months. The results will be compared with anonymized information from your medical records and the care you received before and during your hospital stay.",[28,29,30,31],"Chronic Stress","Cardiac Arrest (CA)","Post-Resuscitation Syndrome","Heart Attack",[33,34,35,36],"cardiac arrest","chronic stress","kortizol","hair","RECRUITING","2026-04-27",{"date":40,"type":41},"2026-05-01","ACTUAL",{"date":43,"type":41},"2026-01-08",{"date":45,"type":22},"2027-10-31",{"name":47,"class":48},"University Hospital Pilsen","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100536957","smartphone-twelve-lead-ecg-utility-in-st-elevation-myocardial-infarction-ii-100536957","NCT06271577","Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II","Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II (STLEUISII)","STLEUISII","Inclusion Criteria:\n\n* Male or female \\> 18 years of age.\n* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.\n* Symptoms of chest pain upon presentation at the Emergency Department of the participating institution.\n\nExclusion Criteria:\n\n* Inability or refusal of the patient and\u002For the patient's legally acceptable representative to provide written informed consent for any reason.\n* Other conditions that in the opinion of the Lead Investigator may increase risk to the subject and\u002For compromise the quality of the clinical trial.",true,{"count":60,"type":22},1000,[25],"AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps. The current Kardia family of devices can measure single lead and six limb-lead ECGs, depending on the device. KardiaMobile, KardiaMobile 6L, and KardiaMobile Card have FDA clearance for ECG rhythm recording. A modified single-lead Kardia smartphone 12-lead ECG was previously validated in the multicenter ST LEUIS study for the diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI).\n\nRecently, AliveCor developed a new device: AliveCor (AC) 12-lead (12L) ECG System to record simultaneously 4 leads of ECG and then generate complete 12-lead ECGs. A previous protocol at the University of Oklahoma involved 200 subjects with early prototypes of the AC 12L device with the specific aim to validate that it accurately generated 12-lead ECGs as compared to simultaneously acquired FDA-cleared 12-lead ECGs. The prototype version of the AliveCor 12L ECG System simultaneously measured four channels of ECG (leads I, II, V2, V4), calculated the remaining limb leads as is standard for 12-lead ECGs (Leads III, aVR, aVL, aVF) and synthesized the remaining 4 precordial ECG leads (V1, V3, V5, V6). This protocol will serve to validate the production version of the system against standard 12-Lead ECGs for the diagnosis of STEMI and NSTEMI in patients admitted to the Emergency Department or directly to the Cardiac Cath Lab for the evaluation of chest pain. It is anticipated that the waveforms for each of the 12 leads from the AC 12L ECG System will be highly correlated with the corresponding leads from the comparator commercially available 12-lead ECG devices used at participating sites. The purpose of this study is to clinically validate that the four-channel AC 12L ECG device can enable the diagnosis of STEMI and NSTEMI in a non-inferior manner to existing 12-lead ECG devices.",[64,65,66,67,68,69,31,70],"Myocardial Infarction","Ischemia","Myocardial Ischemia","Heart Diseases","Cardiovascular Diseases","Vascular Diseases","Heart Failure","2026-04-08",{"date":73,"type":41},"2026-04-09",{"date":75,"type":41},"2024-03-12",{"date":77,"type":22},"2027-03",{"name":79,"class":80},"AliveCor","INDUSTRY",4,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100544852","pharmacy-led-transitions-of-care-intervention-to-improve-medication-adherence-100544852","NCT06374277","Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence","Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations","MedAAAction","Inclusion Criteria:\n\n* Medicaid or uninsured inpatients\n* 21 years or older\n* ≥2 of the complex chronic conditions during index admission or prescribed\u002Fusing ≥2 chronic medications for these conditions\n* Patients receiving chronic disease medications from the hospital pharmacy.\n* Patients will be eligible if they have multiple complex chronic conditions including diabetes, hypertension, high cholesterol, coronary artery disease, congestive heart failure, chronic lung disease, chronic kidney disease, arrhythmia, stroke, psychiatric disorders including depression and anxiety, or who are prescribed or using anticoagulants.\n\nExclusion Criteria:\n\n* Medicare and Medicaid dual eligible patients.\n* If the primary reason for the index admission is related to cancer, pregnancy, or a surgical procedure for an acute problem\n* If patients have diagnoses of active psychosis, substance abuse, or suicidal ideation during the index admission.\n* If the planned discharge location is not home.\n* If patients are part of an existing pharmacy discharge program.",{"count":91,"type":22},388,[25],"Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians\u002Fhealth coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.",[95,96,97,98,99,100,101,102,103,104,105,106,31],"Diabetes","Hypertension","High Cholesterol\u002FHyperlipidemia","Coronary Artery Disease","Congestive Heart Failure","Chronic Lung Disease","Chronic Kidney Diseases","Arrythmia","Stroke","Depression","Anxiety","Pulmonary Embolism","2026-01-27",{"date":109,"type":41},"2026-01-29",{"date":111,"type":41},"2024-04-06",{"date":113,"type":22},"2028-01-31",{"name":115,"class":48},"University of Tennessee",2,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":127,"briefSummary":128,"conditions":129,"keywords":140,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":175},"100523911","coronary-computed-tomography-versus-invasive-angiography-for-non-st-elevation-acute-coronary-syndrome-100523911","NCT06101862","Coronary Computed Tomography Versus Invasive Angiography for Non-ST Elevation Acute Coronary Syndrome","Team-based Interventional Triage in Acute Coronary Syndrome Based on Non-Invasive Computed Tomography Coronary Angiography - a Randomized Trial","TRACTION","Inclusion criteria:\n\n* Admitted with non-ST-segment elevation myocardial infarction or unstable angina pectoris and an indication for subacute ICA\n* Elevated troponin or ischemic electrocardiographic changes\n* Written informed consent\n\nExclusion criteria:\n\n* Instability requiring acute or emergent ICA\n* History of percutaneous coronary intervention or coronary artery bypass grafting\n* Estimated glomerular filtration rate \\< 30 mL\u002Fmin\u002F1.73m2\n* Probable type 2 acute myocardial infarction\n* Severe valvular heart disease as primary diagnosis or potential need for valve intervention\n* History of spontaneous coronary artery dissection\n* Expected poor quality of the CCTA\n* Prior CCTA or ICA during index admission or within 1 week\n* Known allergy to beta-blockers or contrast agent\n* Pregnant or nursing\n* Previously randomized in this trial",{"count":126,"type":22},2300,[25],"Coronary computed tomography angiography (CCTA) is a widely accepted initial diagnostic test for individuals suspected of having chronic coronary syndromes. However, there is limited evidence supporting its use in the acute setting. So far, no large-scale randomized trial has examined the performance of CCTA as an alternative to invasive coronary angiography (ICA) in individuals with non-ST-segment elevation myocardial infarction (NSTEACS).\n\nIf CCTA were to replace ICA as a routine procedure for individuals with NSTEACS, it could reduce the risk of complications related to ICA, improve patient comfort, expedite decision-making, and reduce healthcare expenses and interhospital transfers.",[130,131,132,133,31,134,135,136,137,98,138,139],"Ischemic Heart Disease","Non STEMI","Angina Pectoris, Unstable","Coronary Disease","Acute Myocardial Infarction (AMI)","Randomized Controlled Trial","Diagnostic Imaging","Coronary Stenoses","Multidetector Computed Tomography","Percutaneous Coronary Intervention",[141,142,143,144,145,146,147,148,123,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,66],"Angiography","Computed Tomography","Coronary","Non-STEACS","CCTA","ICA","Randomized","Interventional Triage","Diagnostic imaging","Interventional cardiology","VERDICT","CT","Coronary Angiography","Complications","Coronary CT-team","Ischemic heart disease","Acute myocardial infarction","Non-ST-elevation myocardial infarction (NSTEMI)","Unstable angina pectoris","Percutaneous coronary intervention","Coronary artery bypass grafting","PCI","CABG","Diagnostic procedure","Interhospital transfers","2025-02-14",{"date":168,"type":41},"2025-02-19",{"date":170,"type":41},"2023-10-01",{"date":172,"type":22},"2036-10-01",{"name":174,"class":48},"Rigshospitalet, Denmark",6,{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":49},"100462763","phase-2-sodium-glucose-co-transporter-2-sglt2-and-stemi-100462763","NCT05305911","Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI","Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition Improves Left Ventricular Function and Reduces Adverse Left-Ventricular Remodeling in High-Risk Patients with Microvascular Obstruction (MVO) Following ST-elevation Myocardial Infarction (STEMI).","Inclusion Criteria:\n\n* Patients with their first STEMI (\\>18 years) who underwent successful primary PCI and able to give informed consent\n* At least mild LV dysfunction (LVEF \\\u003C 50%) on echocardiogram, cMRI or Left Ventriculargram following PCI\n* Infarct size that is \\> 10% of LV mass\n* The presence of MVO that is \\> 10% of infarct size\n\nExclusion Criteria:\n\n* Contraindication to cardiac MRI\n* Life expectancy \\\u003C 1 year\n* Previous CABG or Valve Surgery\n* Previous STEMI\n* Pregnant or planning to become pregnant or lactating women\n* Cardiogenic shock (not resolved)\n* Atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding PVCs)\n* GFR\\\u003C30 ml\u002Fmin\u002F1.73m2 or end-stage renal disease on dialysis\n* Type 1 diabetes mellitus or history of diabetic ketoacidosis\n* Type I or II diabetes with insulin use\n* Prior intolerance of SGLT2 inhibitors\n* Current use of SGLT2 inhibitors (randomized patients only)\n* Contraindications to gadolinium","75 Years",{"count":185,"type":22},81,[187],"PHASE2","The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.",[31,190],"Enlarged Heart",[192,193],"Dapagliflozin","Sodium Glucose Co-Transporter 2","2024-10-03",{"date":196,"type":41},"2024-10-08",{"date":198,"type":41},"2022-08-03",{"date":200,"type":22},"2028-12",{"name":202,"class":48},"Minneapolis Heart Institute Foundation"]